title: Clinical applications of hormonal therapy in ovarian cancer.
abstract: The ovary is an endocrine organ and an end organ. Hormones and their receptors have been associated with ovarian cancer and may be related to its causation. Some data suggest that hormonal therapies may have some effect on ovarian cancer in palliative settings. No hormonal therapy is approved by the US Food and Drug Administration (FDA) for the treatment of any type of ovarian malignancy nor is it listed as an active agent by any of the authoritative compendia. Because of the endocrine associations with ovarian cancer, the minimal side effects, and demonstrated activity of hormonal therapies in other endocrine-associated malignancies, further study is needed.
authors.affiliation: University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
authors.forename: Gautam G
authors.initials: GG
authors.lastname: Rao
authors.forename: David S
authors.initials: DS
authors.lastname: Miller
mesh_terms: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000627:therapeutic use; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D016729:Leuprolide; D008525:Medroxyprogesterone
references.citation: Gynecol Oncol. 2002 Sep;86(3):297-301
references.pmid: 12217751
references.citation: J Reprod Med. 1996 Jun;41(6):393-6
references.pmid: 8799913
references.citation: Fertil Steril. 1993 Oct;60(4):672-4
references.pmid: 8405523
references.citation: Gynecol Oncol. 2004 Jul;94(1):25-32
references.pmid: 15262115
references.citation: Gynecol Oncol. 1986 Jul;24(3):299-308
references.pmid: 2424810
references.citation: JAMA. 2003 Oct 1;290(13):1739-48
references.pmid: 14519708
references.citation: Anticancer Drugs. 2001 Oct;12(9):719-24
references.pmid: 11593052
references.citation: Gynecol Oncol. 2003 Dec;91(3):596-602
references.pmid: 14675683
references.citation: Am J Clin Pathol. 2002 May;117(5):745-50
references.pmid: 12090423
references.citation: Semin Oncol. 1986 Dec;13(4 Suppl 4):26-32
references.pmid: 3099393
references.citation: J Nucl Med. 1972 Jan;13(1):101-6
references.pmid: 4332571
references.citation: J Clin Epidemiol. 1990;43(6):559-68
references.pmid: 2348208
references.citation: Gynecol Oncol. 1996 Jul;62(1):4-6
references.pmid: 8690289
references.citation: J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64
references.pmid: 14652237
references.citation: Am J Clin Oncol. 1998 Dec;21(6):565-7
references.pmid: 9856656
references.citation: Acta Oncol. 1995;34(6):813-20
references.pmid: 7576750
references.citation: J Natl Cancer Inst. 2002 Jan 2;94(1):32-8
references.pmid: 11773280
references.citation: Am J Clin Oncol. 1993 Apr;16(2):149-51
references.pmid: 8452108
references.citation: Eur J Cancer. 1994;30A(5):697-8
references.pmid: 8080689
references.citation: Obstet Gynecol. 1989 Dec;74(6):921-6
references.pmid: 2685680
references.citation: Clin Cancer Res. 2002 Jul;8(7):2233-9
references.pmid: 12114425
references.citation: Clin Obstet Gynecol. 2001 Mar;44(1):73-91
references.pmid: 11219248
references.citation: Br J Cancer. 1986 Mar;53(3):321-9
references.pmid: 3083857
references.citation: Cancer Res. 1984 Jun;44(6):2265-71
references.pmid: 6722767
references.citation: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD001034
references.pmid: 20238312
references.citation: Eur J Cancer. 2000 Sep;36 Suppl 4:S59-61
references.pmid: 11056321
references.citation: Oncology. 2004;66(2):112-7
references.pmid: 15138362
references.citation: J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):255-63
references.pmid: 14623519
references.citation: Br J Cancer. 1991 Mar;63(3):410-1
references.pmid: 1825918
references.citation: Bull Cancer. 1995 Jan;82(1):51-6
references.pmid: 7742616
references.citation: Am J Obstet Gynecol. 1985 Dec 15;153(8):877-82
references.pmid: 3000183
references.citation: J Natl Cancer Inst. 1983 May;70(5):839-45
references.pmid: 6405069
references.citation: Breast. 2004 Oct;13(5):363-8
references.pmid: 15454190
references.citation: Am J Clin Oncol. 1992 Apr;15(2):125-8
references.pmid: 1553899
references.citation: Hum Pathol. 1981 Oct;12(10):886-90
references.pmid: 6271662
references.citation: N Engl J Med. 1978 Dec 7;299(23):1261-6
references.pmid: 101843
references.citation: Int J Gynecol Cancer. 1995 Jul;5(4):301-305
references.pmid: 11578494
references.citation: Cancer. 1991 Jul 15;68(2):269-71
references.pmid: 2070324
references.citation: Gynecol Oncol. 2004 May;93(2):390-3
references.pmid: 15099951
references.citation: Gynecol Oncol. 2002 Feb;84(2):201-9
references.pmid: 11812075
references.citation: Ann Oncol. 2002 Feb;13(2):251-7
references.pmid: 11886002
references.citation: Am J Obstet Gynecol. 1989 Oct;161(4):905-10
references.pmid: 2552807